Deciphera Pharmaceuticals : BCR-ABL Program

eciphera's kinase switch inhibitors target the mechanisms that render kinases oncogenic, retain potency against gatekeeper mutations, and afford selectivity profiles not easily attained by other approaches.

BCR-ABL Program

Chronic Myelogeous Leukemia (CML) program

DCC-2036

DCC-2036 inhibits BCR-ABL kinase, an oncogenic fusion protein kinase resulting from chromosomal translocation (Philadelphia + chromosome). BCR-ABL is causative of myeloproliferative diseases, including chronic myelogenous leukemia (CML).

Late-stage preclinical development

Phase 1 trials in CML scheduled for Q1 2009.
» Inhibitor of BCR-ABL and T315I BCR-ABL gatekeeper mutant kinases

Treatment of accelerated/blast crisis CML.
» DCC-2036 inhibits SRC-like kinases LYN, HCK, FGR
Treatment of other myeloproliferative diseases and solid tumors.
» DCC-2036 inhibits TIE2 and KDR kinases, contributing an anti-angiogensis component to its mechanism

In preclinical studies, DCC-2036 has demonstrated potent enzymatic and cellular inhibition of BCR-ABL, the T315I gatekeeper mutant, and other clinically relevant P-loop & Activation loop mutants. DCC-2036 is highly efficacious in animal models of human T315I CML. DCC-2036 is being developed as an orally administered treatment for CML.

DCC-2157

DCC-2157 inhibits BCR-ABL kinase, an oncogenic fusion protein kinase resulting from chromosomal translocation (Philadelphia + chromosome). BCR-ABL is causative of myeloproliferative diseases, including chronic myelogenous leukemia (CML).

CML candidate- preclinical development

Treatment of chronic phase CML.
» Inhibitor of BCR-ABL and T315I BCR-ABL gatekeeper mutant kinases
Treatment of solid tumors.
» DCC-2157 inhibits cKIT, PDGFR-alpha and KDR kinases
» Provides a profile for the treatment of primary GIST and other solid tumors

In preclinical studies, DCC-2157 has demonstrated potent enzymatic and cellular inhibition of BCR-ABL, the T315I gatekeeper mutant, and other clinically relevant P-loop & Activation loop mutants. DCC-2157 is highly efficacious in animal models of human T315I CML. DCC-2157 is being developed as an orally administered treatment for CML.

Deciphera Pharmaceuticals, LLC
4950 Research Park Way
Lawrence, KS 66047

785-838-3767 phone
785-838-3747 fax
info@deciphera.com

	Home \| Senior Management \| Platform \| BCR-ABL \| KIT \| BRAF \| News \| Partners \| Contact
	Copyright © Deciphera Pharmaceuticals, LLC 2002-2009 All Rights Reserved